Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ANDA Sponsors In Drivers Seat For Competitive Generic Therapy Exclusivity

Feb 19 2019

• By Derrick Gingery

Generics

Related Content

Combination Products: US FDA Aims For Limited Two-Application Solutions

Feb 12 2019

New ANDA Review Pathways: Should You Be A Priority Or Expedited?

Nov 13 2017

US FDA’s First Competitive Generic Therapy Approval Comes With A Twist

Aug 10 2018

Lack Of Priority? No ANDAs Approved Using Expedited Pathway In FY 2018

Nov 05 2018

Related Companies

Apotex Inc.

Lupin Limited

Additional Topics

United States Generic Drugs Review Pathway Regulation FDA BioPharmaceutical

More from Generics

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window